EN DE
Watch NicOx S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NicOx S.A. (ALCOX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of NicOx S.A. stock €0.05, price €0.29, that is 82.1% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0013018124

NS NicOx S.A. logo Thin data Nov 3, 2026

NicOx S.A.

ALCOX · PA
Very expensive, in a downtrend

Our calculation puts a fair price 82% below what the stock costs today.

Quality 50/100
Mixed Growth (revenue 5y +5.4 %/yr in EUR)
Mixed vs. peers (5/12)
Fair value €0.0510 · Strongly overvalued
Loss-making · -14.4% net margin (TTM)
High debt
Negative free cash flow
Narrow moat 33/100 · thin data
Thin data
⚠ Dilution
Watch NicOx S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.60 €0.1520 Fair Value €0.0510 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range €0.1520 – €3.60 · fair‑value band €0.0340 – €0.0595 · the €0.2850 price screens above the €0.0510 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow NicOx in your weekly email

Every Wednesday you see whether NicOx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health.

Show moreShow less

The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.

It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation.

In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis.

Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

Stock analysis

NicOx S.A. (ALCOX) currently trades at €0.2850, while our model-based Fair Value estimate is €0.0510, 82% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: €0.0340 (bear) to €0.0595 (bull), the price of €0.2850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

NicOx S.A. reported revenue of €16.8M in FY2025 versus €7.2M in FY2021, a compound +23.4%/yr. Reported net income was −€2.4M in FY2025.

Key figures

Market cap €28.1M Micro · P/S ratio 1.83 · EPS (TTM) €−0.0300 · Net margin −14.4% · Return on equity −51.2% · Return on assets (EBIT) −56.1% (5-year average) · Operating margin 77.3% · Revenue (TTM) €16.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −82%, ALCOX screens richer than that median.

Fair Value models

Bear €0.0340 Fair Value €0.0510 Bull €0.0595
Price €0.2850 · Downside -82.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.0400 €0.0600 €0.0700 55
All 1 models by family
Asset-Based
NCAV (Graham) €0.0400 €0.0600 €0.0700 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 16/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+113.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic). Over 10 years: +5.3% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.4% (2020) → −81.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALCOX screens overvalued: fair value 82% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare NicOx S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −82.1% · Bottom 25%
Profitability
Return on assets −23.3% · Below median
Net margin (12 months) −14.4% · Below median
Operating margin (12 months) 77.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 751.8% · Top 25%
Balance sheet
Debt / equity 2.52× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.68× · Priciest 25%
P/S (12 months) 1.68× · Cheapest 25%
EV/EBITDA 5.9× · Cheapest 25%
PEG 6.24× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ALCOX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ALCOX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs ALCOX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ALCOX
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs ALCOX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ALCOX
argenx SE ARGX $927.21 $908.40 −2% vs ALCOX
CSL Limited CSL A$200.77 A$183.04 −9% vs ALCOX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ALCOX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ALCOX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NicOx S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NicOx S.A. Fair Value". https://www.fairvalue-calculator.com/stock/ALCOX

Frequently asked questions

Is NicOx S.A. (ALCOX) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of €0.0510 versus a price of €0.2850, about 82% lower (overvalued).
What is the fair value of ALCOX?
Our model-based fair value for NicOx S.A. is €0.0510 (as of Nov 3, 2026), built from audited fundamentals. The current price: €0.2850.
What is the quality score of ALCOX?
NicOx S.A. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NicOx S.A. (ALCOX)?
Our model-based price target is the fair value of €0.0510 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario €0.0340, optimistic scenario €0.0595. It is a calculation from audited fundamentals, not an analyst target.
What is the NicOx S.A. stock forecast for 2026?
Our models put fair value at €0.0510, about 82% lower versus a price of €0.2850 (overvalued). Cautious scenario €0.0340, optimistic scenario €0.0595. The calculation is refreshed regularly with new filings.
What is the revenue of NicOx S.A. (ALCOX)?
NicOx S.A. reported trailing-twelve-month revenue of about €16.8M (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of NicOx S.A. (ALCOX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NicOx S.A. it is €0.0510 per share (as of Nov 3, 2026), against a price of €0.2850. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is NicOx S.A. stock overvalued or undervalued in 2026?
As of Nov 3, 2026, ALCOX trades above its calculated fair value: price €0.2850, fair value €0.0510, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALCOX?
No. The price is what the market pays today (€0.2850); the fair value is what the company's own numbers justify (€0.0510). For NicOx S.A. the two are €0.2340 per share apart. That gap is exactly why we show both numbers side by side.
How much is NicOx S.A. worth?
The market values NicOx S.A. at about €28.1M (market capitalisation, as of Nov 3, 2026). Per share that is €0.2850; our models calculate a fair value of €0.0510 per share.
What do the bullish and bearish scenarios say about ALCOX?
Our models span a range for NicOx S.A.: cautious scenario €0.0340, base €0.0510, optimistic €0.0595 per share (as of Nov 3, 2026, price €0.2850). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ALCOX?
The PEG ratio of NicOx S.A. is 6.24 (P/E divided by earnings growth, as of Nov 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of NicOx S.A. (ALCOX)?
Balance-sheet figures for NicOx S.A. (as of Nov 3, 2026): return on equity −51.2%, debt of 2.52 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is ALCOX from its 52-week high?
NicOx S.A. trades at €0.2850, about 44% below its 52-week high of €0.5130 and 1% above the low of €0.2810 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.0510 is for.
Which stocks are comparable to NicOx S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NicOx S.A. stock attractive at the current price?
The data as of Nov 3, 2026: price €0.2850, calculated fair value €0.0510 (−82%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALCOX calculated?
We run NicOx S.A. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.0510 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NicOx S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NicOx S.A. (ALCOX)?
The closing price on Nov 6, 2026 was €0.2850. Our model-based fair value is €0.0510, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NicOx S.A. right now?
The price sits above even our optimistic bull case (€0.0595). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of NicOx S.A.

How large is the market capitalisation of NicOx S.A. (ALCOX)?
The market capitalisation of NicOx S.A. is €28.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NicOx S.A. (ALCOX)?
The price-to-sales ratio of NicOx S.A. is 1.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NicOx S.A. (ALCOX)?
Earnings per share at NicOx S.A. are €−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NicOx S.A. (ALCOX)?
The net margin of NicOx S.A. is −14.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NicOx S.A. (ALCOX)?
The return on equity (ROE) of NicOx S.A. is −51.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NicOx S.A. (ALCOX)?
On an EBIT basis the return on assets of NicOx S.A. is −56.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NicOx S.A. (ALCOX)?
The operating margin of NicOx S.A. is 77.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NicOx S.A. (ALCOX)?
Revenue at NicOx S.A. is growing +752% versus a year earlier (3y avg +72.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NicOx S.A. (ALCOX) generate?
The free cash flow of NicOx S.A. is −€23.2M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does NicOx S.A. (ALCOX) hold?
NicOx S.A. holds more cash than debt, €3.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch NicOx S.A. in the live analysis

One click puts NicOx S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.